[go: up one dir, main page]

AR061785A1 - Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas - Google Patents

Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas

Info

Publication number
AR061785A1
AR061785A1 ARP070102249A ARP070102249A AR061785A1 AR 061785 A1 AR061785 A1 AR 061785A1 AR P070102249 A ARP070102249 A AR P070102249A AR P070102249 A ARP070102249 A AR P070102249A AR 061785 A1 AR061785 A1 AR 061785A1
Authority
AR
Argentina
Prior art keywords
nanoparticles
administration
active molecules
quantian
hialuronan
Prior art date
Application number
ARP070102249A
Other languages
English (en)
Inventor
Fernandez Maria Jose Alonso
La Fuente Freire Maria De
Pena Ana Isabel Vila
Rey Maria Begona Seijo
Original Assignee
Advanced In Vitro Cell Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06380132A external-priority patent/EP1859792A1/en
Application filed by Advanced In Vitro Cell Tech filed Critical Advanced In Vitro Cell Tech
Publication of AR061785A1 publication Critical patent/AR061785A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Sistema de nanopartículas util para la administracion de moléculas farmacologicamente activas, y especialmente para transfectar polinucleotidos dentro de células. Comprende nanopartículas de quitosano de bajo peso molecular e hialuronano. Composiciones farmacéuticas y cosméticas que lo contienen y uso del sistema para terapia génica.
ARP070102249A 2006-05-24 2007-05-24 Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas AR061785A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380132A EP1859792A1 (en) 2006-05-24 2006-05-24 Nanoparticles of chitosan and hyaluronan for the administration of active molecules
EP06124177 2006-11-16

Publications (1)

Publication Number Publication Date
AR061785A1 true AR061785A1 (es) 2008-09-24

Family

ID=38577658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102249A AR061785A1 (es) 2006-05-24 2007-05-24 Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas

Country Status (8)

Country Link
US (1) US20110142890A1 (es)
EP (1) EP2026772A1 (es)
JP (1) JP2009537604A (es)
KR (1) KR20090031861A (es)
AR (1) AR061785A1 (es)
CA (1) CA2652530A1 (es)
IL (1) IL195316A0 (es)
WO (1) WO2007135164A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2164964T3 (da) * 2007-07-06 2011-12-05 Univ Aarhus Dehydrerede chitosanpartikler
WO2009035438A1 (en) * 2007-09-13 2009-03-19 Janos Borbely Polymeric nanoparticles by ion-ion interactions
ES2345806B1 (es) * 2009-03-30 2011-07-22 Universidad De Santiago De Compostela Sistemas nanoparticulares elaborados a base de polimeros anionicos para administrar moleculas bioactivas para uso cosmetico.
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
ES2351756B1 (es) * 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
KR101138258B1 (ko) * 2009-12-09 2012-04-24 (주)바이오제닉스 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법
FR2963351B1 (fr) * 2010-07-30 2013-03-08 Univ Claude Bernard Lyon Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree
GB201017889D0 (en) * 2010-10-22 2010-12-01 Univ Dublin A polymeric nanoparticle
US8897536B2 (en) * 2011-04-24 2014-11-25 Universidade Da Coruna. Otri Molecular block-matching method for gel image analysis
US8968790B2 (en) 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
WO2013166616A1 (es) * 2012-05-11 2013-11-14 Universidad Austral De Chile Biomaterial que comprende quitosano y al menos glicosaminoglicano
JP6120397B2 (ja) * 2012-10-11 2017-04-26 ポーラ化成工業株式会社 キトサン及びヒアルロナンを含むナノ粒子の製造方法
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
WO2016066864A1 (es) 2014-10-30 2016-05-06 Innovaciones Fisicas Y Quimicas Sostenibles, S.L. Nanopartículas para la liberación controlada de ingredientes activos
US20180028458A1 (en) * 2015-02-09 2018-02-01 Polyvalor, Société En Commandite (S.E.C.) Coated chitosan-based polyplex for delivery of nucleic acids
KR102301452B1 (ko) 2016-10-17 2021-09-10 포라 가세이 고교 가부시키가이샤 음이온성 폴리머 및 양이온성 폴리머 또는 펩티드를 포함하는 복합 입자 및 이의 제조 방법
WO2018143493A1 (ko) * 2017-02-03 2018-08-09 서강대학교 산학협력단 아토피 질환 치료용 siRNA 하이드로젤 기반 나노입자 및 이의 제조방법
WO2018190755A1 (en) * 2017-04-10 2018-10-18 King Abdulaziz City For Science And Technology Protein functionalized hyaluronic acid coated chitosan nanoparticle and method of preparation
JP7536018B2 (ja) * 2019-08-21 2024-08-19 株式会社 資生堂 化粧料
AU2022206798B2 (en) 2022-07-21 2025-07-03 Taipei Medical University Self-assembled nanoparticle and use thereof for anti- angiogenesis
CN118846249B (zh) * 2024-06-26 2025-10-24 吉林大学 一种cs-ha纳米粒子交联的胶原蛋白盾及其制备方法
CN118873638B (zh) * 2024-07-08 2025-07-25 北京化工大学 一种具有抗菌抗炎功能的透明质酸/聚阳离子级联蛋白制剂的制备方法及产品和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268476A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US20010053359A1 (en) * 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
FR2777193B1 (fr) * 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
DE10050870A1 (de) * 2000-10-11 2002-08-01 Knoell Hans Forschung Ev Biokompatibles Verbundmaterial für medizinische Anwendungen
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.

Also Published As

Publication number Publication date
EP2026772A1 (en) 2009-02-25
WO2007135164A1 (en) 2007-11-29
IL195316A0 (en) 2009-08-03
CA2652530A1 (en) 2007-11-29
US20110142890A1 (en) 2011-06-16
KR20090031861A (ko) 2009-03-30
JP2009537604A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
AR061785A1 (es) Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas
ZA202103233B (en) Lipid nanoparticle formulations
Hadinoto et al. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
BR112014027834A2 (pt) composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
BR112012023638A2 (pt) Sistema de entrega, composição cosmética, farmacêutica e/ou alimentar e uso da composição cosmética, farmacêutica e/ou alimentar
BR112015018087A8 (pt) composto, composição farmacêutica e uso
WO2008129106A3 (es) Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EA201200604A1 (ru) Фармацевтические субстанции на основе митохондриальноадресованных антиоксидантов

Legal Events

Date Code Title Description
FB Suspension of granting procedure